Comparative Pharmacology
Head-to-head clinical analysis: DEMULEN 1 35 21 versus NORINYL 1 80 21 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMULEN 1 35 21 versus NORINYL 1 80 21 DAY.
DEMULEN 1/35-21 vs NORINYL 1+80 21-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol (estrogen) and ethynodiol diacetate (progestin). Inhibits gonadotropin secretion (FSH, LH) via negative feedback on hypothalamic-pituitary axis, suppressing ovulation. Additionally, thickens cervical mucus and alters endometrial receptivity.
Combination oral contraceptive containing norethindrone (a progestin) and ethinyl estradiol (an estrogen). Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial morphology.
One tablet orally once daily for 21 days, followed by 7 days off. Each tablet contains 1 mg ethynodiol diacetate and 35 mcg ethinyl estradiol.
One tablet orally once daily for 21 days, followed by 7 days of no active treatment.
None Documented
None Documented
Ethinyl estradiol: 13±3 hours (terminal); norethindrone: 8±3 hours. Steady-state achieved after ~5 days.
Norethindrone: 8-11 hours; Mestranol: 12-24 hours (metabolized to ethinyl estradiol with half-life 20-27 hours). Steady-state after 5-7 days.
Renal (primarily as glucuronide and sulfate conjugates): ~60%; fecal: ~40%
Renal (40-60% as metabolites), fecal (20-30%)
Category C
Category C
Oral Contraceptive
Oral Contraceptive